Trial Profile

A Randomized, Global Study of Resolute Onyx Drug-Eluting Stent and One-Month Dual Antiplatelet Therapy

Status: Recruiting

Phase of Trial: Phase IV

Latest Information Update: 21 Dec 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Zotarolimus (Primary) ; Aspirin
Indications Coronary artery disease; Coronary artery restenosis
Focus Adverse reactions
Acronyms RESOLUTE ONYX ONE-MONTH DAPT

Most Recent Events

21 Dec 2020 Status changed from not yet recruiting to recruiting as per results presented at the 32nd Annual Scientific Symposium on Transcatheter Cardiovascular Therapeutics
23 Aug 2017 New trial record
14 Aug 2017 According to a Medtronic media release, Stephan Windecker, M.D., of Bern University Hospital in Switzerland is the principal investigator of the study.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com